Last reviewed · How we verify
Preservative
At a glance
| Generic name | Preservative |
|---|---|
| Sponsor | Ifocus Oyeklinikk |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- The Development of New Functions of Esculin and Digitalis Glycosides Eye Drops: A Study on the Treatment of Presbyopia (PHASE4)
- Indigenous Nutritional Supplements for Pregnancy to Improve Resilience in Environmental Heat (NA)
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes (PHASE3)
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preservative CI brief — competitive landscape report
- Preservative updates RSS · CI watch RSS
- Ifocus Oyeklinikk portfolio CI